Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference by Munteanu, M. et al.
Diagnostic performance of FibroTest, SteatoTest and ActiTest in
patients with NAFLD using the SAF score as histological reference
M. Munteanu*, D. Tiniakos†,‡, Q. Anstee†, F. Charlotte§, G. Marchesini¶, E. Bugianesi**, M. Trauner††,
M. Romero Gomez‡‡, C. Oliveira§§, C. Day†, J.-F. Dufour¶¶, S. Bellentani***, Y. Ngo*, S. Traussnig††, H. Perazzo†††,
O. Deckmyn*, P. Bedossa‡‡‡, V. Ratziu§, T. Poynard§ & the FLIP Consortium and the FibroFrance Groupa
*BioPredictive, Paris, France.
†Liver Research Group, Institute of Cellular
Medicine, Newcastle University, Newcastle-
upon-Tyne, UK.
‡Laboratory of Histology & Embryology,
Medical School, National & Kapodistrian
University of Athens, Greece.
§Groupe Hospitalier Pitie Salpe^triere APHP,
Sorbonne Universites, UPMC Univ Paris 06,
INSERM, UMR_S 938 & Institute of
Cardiometabolism and Nutrition (ICAN), Paris,
France.
¶Universita di Bologna, Bologna, Italy.
**Universita Degli Studi di Torino, Torino, Italy.
††Medizinischen Universitaet Wien, Vienna,
Austria.
‡‡Valme University Hospital, University of
Seville, Sevilla, Spain.
§§Department of Gastroenterology (LIM-
07), University of S~ao Paulo School of
Medicine, S~ao Paulo, Brazil.
¶¶Universite de Berne, Berne, Switzerland.
***Gastroenterologia, Azienda USL di
Modena Reggio Emilia, Modena, Italy.
†††APHP UPMC Liver Center, Paris, France.
‡‡‡Assistance Publique-Ho^pitaux de Paris,
ho^pital Beaujon, University Paris-Diderot,
Paris, France.
Correspondence to:
Prof. T. Poynard, Hepato-Gastroenterology
Department, Groupe Hospitalier Pitie
Salpe^triere, Paris 75013, France.
E-mail: thierry@poynard.com
aCo-authors members of the FLIP
Consortium and the FibroFrance Group are
listed in Appendix 1.
Publication data
Submitted 17 June 2016
First decision 19 July 2016
Resubmitted 26 July 2016
Accepted 27 July 2016
EV Pub Online 23 August 2016
The Handling Editor for this article was
Professor Peter Hayes, and it was accepted for
publication after full peer-review.
SUMMARY
Background
Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease
(NAFLD) than in patients with chronic viral hepatitis.
Aims
To improve the validation of three blood tests used in NAFLD patients, FibroTest
for ﬁbrosis staging, SteatoTest for steatosis grading and ActiTest for inﬂammation
activity grading.
Methods
We pre-included new NAFLD patients with biopsy and blood tests from a single-cen-
tre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporane-
ous biopsies were blindly assessed using the new steatosis, activity and ﬁbrosis (SAF)
score, which provides a reliable and reproducible diagnosis and grading/staging of
the three elementary features of NAFLD (steatosis, inﬂammatory activity) and ﬁbro-
sis with reduced interobserver variability. We used nonbinary-ROC (NonBi-
nAUROC) as the main endpoint to prevent spectrum effect and multiple testing.
Results
A total of 600 patients with reliable tests and biopsies were included. The mean
NonBinAUROCs (95% CI) of tests were all signiﬁcant (P < 0.0001): 0.878 (0.864–
0.892) for FibroTest and ﬁbrosis stages, 0.846 (0.830–0.862) for ActiTest and activ-
ity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest
had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4
(0.845; 0.829–0.861; P = 0.007) but not signiﬁcantly different than the NAFLD
score (0.866; 0.850–0.882; P = 0.26). FibroTest had a signiﬁcant difference in med-
ian values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and
NAFLD scores (Bonferroni test P < 0.05).
Conclusions
In patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests
that offer an alternative to biopsy, and they correlate with the simple grading/stag-
ing of the SAF scoring system across the three elementary features of NAFLD:
steatosis, inﬂammatory activity and ﬁbrosis.
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INTRODUCTION
As stated in recent guidelines and overviews, serum
biomarkers of liver injury have been less well validated
in non-alcoholic fatty liver disease (NAFLD) than in
chronic viral hepatitis.1, 2 One reason was that the histo-
logical systems previously used as references when
assessing biomarker performance in NAFLD were less
consensual, mixing different elementary histological fea-
tures, than with chronic viral hepatitis in which ﬁbrosis,
activity and steatosis were separately scored.3–5 Examples
of such dependence between elementary features in
NAFLD diagnosis were the exclusion of non-alcoholic
steato-hepatitis (NASH) in cases with activity but with-
out steatosis, or the diagnostic of NASH in cases with
steatosis and ﬁbrosis but without activity.3, 4
In viral hepatitis, the METAVIR (META-analysis of
histological data in VIRal hepatitis) scoring system,
which has been widely validated since 1996, is used to
independently classify ﬁbrosis based on ﬁve classes, and
the necro-inﬂammatory histological activity grade based
on four classes.5 Since 2012, the SAF score (Steatosis,
inﬂammatory Activity and Fibrosis) has provided reliable
and reproducible diagnoses and grading/staging of the
three elementary features of NAFLD with reduced inter-
observer variability.3, 4
The diagnostic performance of speciﬁc blood tests of
SAF in NAFLD has previously been validated using a
range of nonconsensual scoring systems for NAFLD: six
studies for FibroTest (Nash-FibroSure in USA) using the
METAVIR ﬁbrosis score,6–11 three studies for ActiTest
using the METAVIR activity score 7, 10, 12 and three
studies for SteatoTest using the Goodman steatosis
score.9, 10, 13 FibroTest and SteatoTest have been already
used as secondary efﬁcacy endpoints in clinical trials of
patients with presumed NAFLD or NASH.14–16 In this
report, we aimed to improve the validation of these three
blood tests in patients with NAFLD using the new SAF
scoring system as the histological reference.
PATIENTS AND METHODS
We included a large group of new patients from the
ongoing FibroFrance project (USA-NCT01927133), and
the prospective population of the FLIP consortium
(http://www.ﬂip-fp7.eu/). Instead of the binary area
under the operating characteristic curves (AUROC), the
nonbinary area under the operating characteristic curves
(NonBinAUROC or Obuchowski measure) was the pri-
mary endpoint for assessing the nonbinary performances
of these tests and as recommended for preventing the
spectrum effect and multiple testing.17–19
The FLIP project (Fatty Liver: Inhibition of Progression
EU-241762) was initiated in 2010. Two speciﬁc aims of the
project were the validation of improved diagnostic and
prognostic markers, and the validation of a consensual his-
tological classiﬁcation of NAFLD and NASH. The project
was based on a large prospective European cohort of
patients with histologically diagnosed NAFLD, with stan-
dardised inclusion criteria and histologically proven
NAFLD, with and without NASH. (http://www.ﬂip-fp7.eu/)
Written patient consent for liver biopsy and data collection
was obtained from each subject prior to inclusion.
The FibroFrance project was initiated in 1996. The
aim of this project was to assess the natural history of
liver ﬁbrosis in chronic liver diseases and the impact of
treatments.20–23 This epidemiological, non-interventional
study was exempt from IRB review (Ethical committee
of ‘Comite de Protection des Personnes of Paris- Ile-de-
France’, FIBROFRANCE project. CPP-IDF-VI, 10-1996-
DR-964, DR-2012-222 and USA-NCT01927133). No
consent was given, as all data were analysed anony-
mously. All clinical investigations were conducted
according to the principles expressed in the Declaration
of Helsinki. All authors had access to the study data and
reviewed and approved the ﬁnal manuscript.
Patients
The inclusion criteria in the prospective FLIP cohort were
adult patients at risk of NAFLD, i.e. presenting with
ultrasound deﬁned steatosis, and/or increased liver func-
tion test values, and/or metabolic risk factors (overweight,
visceral adiposity, type 2 diabetes, arterial hypertension,
dyslipidemia) without well identiﬁed chronic liver dis-
eases including alcohol consumption of <50 g/day. All
patients had to have had a liver biopsy. The nine partici-
pating centres were located in Paris, Seville, Newcastle,
Bologna, Turin, Modena, Sao Paulo, Bern and Vienna. A
central e-CRF was created, and data quality was enforced
by a central data manager. The inclusion criteria in this
retrospective analysis were the presence of reliable
FibroTest, ActiTest and SteatoTest (FibroMax package),
as well as the reading of the biopsy using the SAF scoring
system by one of the experts from the FLIP Pathology
Consortium. The validation of the patented FibroMax
package was pre-determined in the FLIP protocol aims
before patient inclusion (http://www.ﬂip-fp7.eu/).
The inclusion criteria of the FibroFrance-NAFLD
population were the same as in FLIP cohort, and with
measurements of SteatoTest, ActiTest and FibroTest
(USA-NCT01927133). The criterion for retrospective
inclusion in the FibroFrance-FibroMax subpopulation
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was the reading of a liver biopsy using the SAF scoring
system by one of the experts from the FLIP Pathology
Consortium. Patients from both cohorts were excluded if
the blood test was disqualiﬁed according to the company
recommendations for reliable tests,24 or if the interval
between the biopsy and blood tests was greater than
180 days. Patients receiving speciﬁc treatment for
NAFLD before biopsy, were not included.
Histological references
The SAF scoring system, speciﬁc for NAFLD features,
has been described elsewhere.3, 4 The goal of the SAF
test was to ﬁnd a compromise between the development
of a simple, easily applied system for making a ﬁrm
diagnosis in individual patients, even when applied by
nonspecialists, and of a more reliable and discriminating
system for therapeutic trials or for the assessment of bio-
marker diagnostic performance. A FLIP histopathology
consortium of eight members developed the FLIP algo-
rithm, a diagnostic tool for the diagnosis and staging of
severe forms of NAFLD.3, 4 According to the combina-
tion of each semi-quantiﬁcation of the three elementary
features of NAFLD using the SAF score for steatosis,
inﬂammatory activity and ﬁbrosis respectively. The
steatosis score (S) assesses the quantities of large or med-
ium-sized lipid droplets, with the exception of foamy
microvesicles, and rates them from 0 to 3 (S0: <5%; S1:
5–33%, mild; S2: 34–66%, moderate; S3: >66%, marked).
Activity grade (A, from 0 to 4) is the unweighted addi-
tion of hepatocyte ballooning (0–2) and lobular inﬂam-
mation (0–2). Cases with A0 (A = 0) had no activity; A1
(A = 1) had mild activity; A2 (A = 2) moderate activity;
A3 (A = 3) severe activity and A4 (A = 4) had very sev-
ere activity. Fibrosis stage (F) was assessed using the
score described by25 as follows: stage 0 (F0) = none;
stage 1 (F1) = 1a or 1b perisinusoidal zone 3 or 1c por-
tal ﬁbrosis; stage 2 (F2) = perisinusoidal and periportal
ﬁbrosis without bridging; stage 3 (F3) = bridging ﬁbrosis
and stage 4 (F4) = cirrhosis (File S1).
To reduce interobserver variability and homogenise the
reading using the new SAF-FLIP histological classiﬁcation,
we used only reports reviewed by members of the FLIP
Pathology Consortium (DT and PB for the FLIP subpopu-
lation and FC for the FibroFrance subpopulation).
Blood tests
FibroTest, ActiTest and SteatoTest were patented as the
‘In Vitro Diagnostic Multivariate Index Assay’ for the
diagnosis of METAVIR ﬁbrosis stages, including cirrho-
sis, for METAVIR activity grades and for SAF-equivalent
steatosis grades.10, 22–24 FibroTest included serum a2-
macroglobulin, apolipoprotein A1, haptoglobin, total
bilirubin and gamma-glutamyltranspeptidase, adjusted
for age and gender. ActiTest included the same compo-
nents plus alanine-aminotransferase (ALT). SteatoTest
included the same six components of FibroTest-ActiTest
plus body mass index, serum cholesterol, triglycerides
and glucose, adjusted for age and gender.13 These tests
are exclusively available online, including security algo-
rithms. Modelling of ﬁbrosis progression or regression
and prognostic performances were similar when FibroT-
est was compared to liver biopsy, regardless of the cause
of liver disease,8, 22, 26–30 including the same limitations
for discriminating between intermediate stages of ﬁbro-
sis.31 The recommended cutoffs were the same whatever
the chronic liver diseases (File S1).
The following three blood tests were used as compara-
tors for FibroTest, as recommended in the NAFLD guide-
lines3: (i) NAFLD Fibrosis Score (NFS) = (1.675 +
0.037 9 age (year) + 0.094 9 BMI (kg/m2) + 1.13 9
IFG/diabetes (yes = 1, no = 0) + 0.99 9 AST/ALT ratio
 0.013 9 platelet count (9109/L)  0.66 9 albumin
[g/dL]); (ii) BARD score (BMI ≥28 = 1; AST/ALT ratio
≥0.8 = 2; diabetes = 1; score ≥2, odds ratio for advanced
ﬁbrosis = 17); and (iii) FIB4 score = FIB-4 = age
(year) 9 AST [U/L]/(platelets [109/L] 9 (ALT [U/L]). No
guidelines proposed recognised blood tests as comparators
of SteatoTest for steatosis grades and of ActiTest for activ-
ity grades.1
Statistical analysis
The protocol and the analyses followed the FibroSTARD
recommendations, which are detailed in File S2.19 In
summary, we checked that the study populations had
not been previously used and published for the evalua-
tion of the studied tests. In the FLIP group, all the cases
were prospective, and the tests, as well as the contempo-
raneous biopsies, had not been previously published. In
the FibroFrance cases, no patients had been published in
previous validations of FibroTest, ActiTest or SteatoTest
in NAFLD.6, 10, 12, 13
The primary endpoint for the diagnostic performance
for each quantitative test, for the diagnostic of each his-
tological class (SAF scoring system), was the NonBi-
nAUROC: FibroTest for the ﬁve SAF ordinal stages of
ﬁbrosis (F0–F4), ActiTest for the ﬁve ordinal SAF grades
(A0–A4) and SteatoTest, for the four ordinal grades (S0–
S3) (File S1). The penalty function was related to the
number of classes difference: for ﬁve classes, 0.25 for one
class difference (adjacent classes), 0.50 for two for and
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0.75 for three. We also graphically represented the medi-
ans and the interquartile distribution of all tests accord-
ing to histological scores. The medians were compared
using the Kruskal–Wallis multiple comparisons Z-Value
test, with the Bonferroni correction due to the number
of comparisons.
The secondary endpoint was the comparisons between
ﬁbrosis blood tests. The performances of FibroTest and
ActiTest were compared to those of NAFLD score,
BARD and FIB4, also used for assessing the severity of
ﬁbrosis and activity in subjects with presumed NAFLD.
Sensitivity analyses of the primary endpoint (NonBi-
nAUROC) used stratiﬁcations according to the following
known factors of variability in the tests’ performances:
biopsy length (≤10 mm, 10 mm to <20 mm and
≥20 mm),32 morbid obesity (>35 kg/m2)10 and presence
of diabetes (fasting glucose ≥7.0 lmol). We also com-
pared the NonBinAUROC between the FibroFrance-
NAFLD cohort and the non-French FLIP cohort.
The statistical softwares NCSS-2013 33 and R-nonBin-
ROC were used.34
RESULTS
From March 2005 to December 2014, a total of 956 patients
with suspected NAFLD were pre-included, and 600 patients
were included after exclusion of 356 patients due to the
absence of blood tests (n = 305) or of biopsy as assessed by
the SAF score (n = 14) or with more than 180 days
between biopsy and tests (n = 44) (Figure 1). The charac-
teristics of included and excluded patients were very similar,
with a median age of 50 years, 60% male, BMI 30 kg/m2,
23% type 2 diabetics, and 5% histological cirrhosis, despite
a lower prevalence of stage F0 in included (20.3%) than in
excluded patients (29.9%) (Table 1).
Primary endpoint (Table 2)
The mean (95% CI) NonBinAUROC of tests were all
signiﬁcant (P < 0.0001): 0.878 (0.864–0.892) for FibroT-
est and the prediction of ﬁve SAF ﬁbrosis stages, 0.846
(0.830–0.862) for ActiTest and ﬁve SAF-activity grades,
and 0.822 (0.804–0.840) for SteatoTest and four SAF
steatosis grades. The highest performances between adja-
cent stages/grades were observed for F3 vs. F4, A3 vs.
A4 and S0 vs. S1; the lowest performances were observed
for F0 vs. F1, A2 vs. A3 and S1 vs. S2 (File S3).
Comparison between ﬁbrosis tests (Table 3)
In 574 patients with all blood tests, for the prediction of
ﬁbrosis stages, FibroTest had a higher NonBinAUROC
(0.877; 0.862–0.892) than BARD (0.836; 0.820–0.852;
P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but
not signiﬁcantly higher than NAFLD score (0.866;
0.850–0.882; P = 0.26).
ActiTest for the prediction of necro-inﬂammatory
activity grades, had a higher NonBinAUROC (0.846;
0.830–0.862) than BARD (0.810; 0.792–0.828;
P = 0.0003), FIB4 (0.798; 0.780–0.816; P < 0.0001) and
than NAFLD score (0.815; 0.805–0.825; P = 0.005).
Box plots of test values according to biopsy scores
are given in Figure 2a for FibroTest. The median
FibroTest values increased (P < 0001) steadily with
ﬁbrosis stages after F1, ranging from 0.18 in F0, 0.21 in
F1, 0.28 in F2, 0.41 in F3 and 0.71 in cirrhosis
(Table S4B in File S4). Only FibroTest had a signiﬁcant
difference in median values (Bonferroni test) between
adjacent stage F2 and stage F1 (Table S4A in File S4)
when compared to FIB4 (Figure S4B and Table S4B in
File S4), to BARD (Figure S4C and Table S4C in File
S4) and to NAFLD score (Figure S4D and Table S4D
in File S4).
ActiTest and SAF-activity score
The median value of ActiTest increased steadily
(P < 0.001) from 0.21 for A0, 0.28 for A1, 0.35 for A2
and 0.38 for A3 and 0.46 for the last grade of SAF scor-
ing system (Figure 2b, Table S5A in File S5); differences
however were only signiﬁcant between 2 grades using
the multiple comparisons rules. The ActiTest median
values increased (P < 0.001) for the two features of the
SAF-activity score, ballooning and lobular inﬂammation.
For ballooning, the value was 0.22 if absence (n = 116),
0.36 if moderate (n = 253) and 0.39 if severe (n = 231),
with a signiﬁcant difference between grades 0 and 1 (Fig-
ure S5B and Table S5B in File S5). For lobular inﬂam-
mation, the value was 0.23 if absence (n = 118), 0.35 if
moderate (n = 331), and 0.43 if severe (n = 151), all
with signiﬁcant differences between adjacent stages (Fig-
ure S5C and Table S5C in File S5).
SteatoTest and SAF steatosis score
Only 20 patients had an S0 grade, which was expected
due to the inclusion criteria of NAFLD patients. The
median value of SteatoTest increased (P = 0.002) from
0.52 for S0 (n = 20), 0.62 for S1 (n = 188), 0.66 for S2
(n = 228), to 0.71 for S3 (n = 163), marked steatosis the
last grade. The only signiﬁcant difference observed
between grades was between S3 and S1 (Figure 2c, Fig-
ure S6A and Table S6A in File S6).
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Sensitivity analyses
File S7 shows the sensitivity analyses of the test perfor-
mances on the primary outcome (NonBinAUROC)
according to gender, cohorts, biopsy length, diabetes and
severe obesity. There were no signiﬁcant differences
between the NonBinAUROC stratiﬁed according the
variability factors for FibroTest (Table S7A in File S7),
ActiTest (Table S7B in File S7) or SteatoTest (Table S7C
in File S7).
DISCUSSION
The results of this large sample of NAFLD patients con-
ﬁrmed the signiﬁcant performance previously observed
for FibroTest,6–11 ActiTest7, 10, 12 and SteatoTest.9, 10, 13
The 2015 EASL guidelines had not yet reviewed the
recent validations by external researchers (‘independent
of inventor’s team’) for the diagnosis of NAFLD features,
including FibroTest or ActiTest, or SteatoTest.8, 9, 11
Despite many advantages of these tests, as in patients
with chronic viral hepatitis, several limitations must be
acknowledged.
Limitations
The patients included for possible NAFLD were mostly
those from tertiary centres whose selection was based on
abnormal tests, which may not be representative of
NAFLD in the general population. Indeed, the spectra of
ﬁbrosis stages, activity and steatosis grades were much
more severe in this study than those of NAFLD
(n = 3969) as screened in the French general popula-
tion27: 6.2% cirrhosis as presumed by FibroTest vs. 0.4%
(0.2–0.6%); 20.0% severe activity (grades A3 and A4) as
presumed by ActiTest vs. 0.81% (32/3969); and 48.3%
moderate/marked steatosis (S2/S3) as presumed by Stea-
toTest vs. 13.4% (525/3934) respectively. The mean BMI
of 30 kg/m2 indicated a high prevalence of obese with a
low prevalence of fatty liver occurring in slightly over-
weight individuals. Median age was 50 years, again
FLIP Cohort without French
n = 515
FibroFrance Cohort
n = 441
356 excluded
37 no biopsy SAF scored
305 FibroMax not performed
2 FibroMax not-reliable
14 interval >= 4 year
0 excluded
0 no biopsy SAF scored
0 FibroMax not performed
0 FibroMax not-reliable
0 interval>4 year
All FLIP chart without French
included n = 159
SAF biopsy and blood tests reliable
FLIP French
Patients n = 90
All FLIP included
n = 249
SAF biopsy and blood tests reliable
FibroFrance NAFLD Cohort
n = 351
SAF biopsy and blood tests reliable
n = 356
Excluded
n = 600
Included
Figure 1 | Flow charts of patient inclusions.
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indicating a previous selection of patients. Thus individ-
uals, who might have had NAFLD for a signiﬁcant dura-
tion to have progressed, limiting the ﬁndings in relation
to early detection of NAFLD. In addition, another limita-
tion was the predominance of Caucasians. The advan-
tages of these blood tests were the broad spectrum of
Table 1 | Characteristics of included and excluded patients
Characteristics Included (n = 600) Excluded (n = 356) P-value
FibroFrance NAFLD 441/600 (73.5%) 356/356 (100%)
Non-French FLIP 159/600 (26.6%) 0/355 (0.0%) <0.0001
Gender male 380/600 (63.3%) 218/356 (61.4%) 0.52
Diabetes type 2 136/600 (22.7%) 81/347 (23.3%) 0.87
Age (years) 53.2 (51.4–54.4) 51.3 (49.7–53.0) 0.04
BMI (weight/height2) 29.7 (29.2–30.2) 29.9 (29.2–30.7) 0.62
Biopsy length (mm)* 25 (22–25) 15 (15–18) 0.0001
Number fragments† 2 (1–2) 1 (1–1) 0.0001
Number portal tracts‡ 16 (15–17) NA NA
Interval between biopsy and test (days) 0 (0–0.015) 0 (0–4.1) 0.0001
SAF F biopsy
F0 no ﬁbrosis 122/600 (20.3%) 102/342 (29.9%) 0.02
F1 perisinusoidal or portal 184/600 (30.8%) 83/342 (24.0%)
F2 sinusoidal or periportal without bridging 140/600 (23.3%) 77/342 (22.6%)
F3 bridging ﬁbrosis 121/600 (20.2%) 61/342 (17.9%)
F4 cirrhosis 33/600 (5.5%) 19/342 (5.6%)
Grade of activity (SAF A biopsy)
A0 no activity 64/600 (10.7%) 32/320 (10.0%) 0.09
A1 mild 86/600 (14.3%) 65/320 (20.3%)
A2 moderate 191/600 (31.8%) 81/320 (25.3%)
A3 severe 156/600 (26.0%) 81/320 (25.3%)
A4 very severe 103/600 (17.2%) 81/320 (19.1%)
SAF S biopsy
S0 no steatosis <5% 20/600 (3.3%) 7/339) (2.1%) 0.33
S1 mild 5–33% 204/600 (34.0%) 115/339 (33.9%)
S2 moderate 34–66% 229/600 (38.2%) 125/339 (36.9%)
S3 marked >66% 147/600 (24.5%) 92/339 (27.1%)
Presumed Fibrosis SAF stage (FibroTest range)
F0 no ﬁbrosis (0.00–0.27) 314/600 (52.3%) 23/50 (46.0%) 0.17
F1 (>0.27–0.48) 149/600 (24.8%) 12/50 (24.0%)
F2 (>0.48–0.58) 39/600 (6.5%) 6/50 (12.0%)
F3 (>0.48–0.74) 64/600 (10.7%) 3/50 (6.0%)
F4 (>0.74–1.00) 34/600 (5.7%) 6/50 (12.0%)
Presumed SAF-activity grade (ActiTest range)*
A0 no activity (0.00–0.29) 262/600 (43.7%) 27/50 (54.0%) 0.04
A1 mild (>0.29–0.52) 185/600 (30.8%) 10/50 (20.4%)
A2 moderate>0.52–0.62) 62/600 (10.3%) 3/50 (6.0%)
A3 severe grades (>0.62–0.72) 33/600 (5.5%) 7/50 (14.0%)
A4 very severe grades (>0.72–1.00) 58/600 (9.1%) 3/50 (6.0%)
Presumed SAF Steatosis (SteatoTest range)
S0 no steatosis 0–<5% (0.00–0.57) 228/600 (15.7%) 10/45 (6.7%) 0.10
S1 mild >5%–≤33% (>0.57–0.69) 116/600 (19.3%) 12/45 (26.7%)
S2S3 > moderate-marked >33% (>0.69–1.00) 256/600 (42.7%) 23/45 (51.1%)
Presumed steatosis including minimal grade
S0 no steatosis 0% (0.00–0.38) 94/600 (15.7%) 3/45 (6.7%) 0.17
S1 minimal 1–5% (>0.38–0.57) 134/600 (22.3.0%) 7/45 (15.6%)
S2 mild >5% to ≤33% (>0.57–0.69) 116/600 (19.3%) 12/45 (26.7%)
S3S4 > moderate-marked >33% (>0.69–1.00) 256/600 (42.7%) 23/45 (51.1%)
* Data available in 510 included and 325 excluded patients.
† Data available in 346 included and 0 excluded patients.
‡ Data available in 268 included and 188 excluded patients.
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validations in a variety of populations, from controls,
blood donors and cured chronic hepatitis C (CHC) to
populations at high risk of NAFLD including diabetes,
severe obesity and dyslipidemia.13, 26, 30, 35–37
FibroTest had limitations in NAFLD patients, as it
was not initially designed to discriminate between the
zonal distribution of ﬁbrosis, which is different than the
portal distribution of ﬁbrosis in chronic viral hepatitis.
However, the prognosis of ﬁbrosis staged using the
‘METAVIR ﬁbrosis stages’ based on few septa (F2) and
many septa (F3) was validated for the most frequent
chronic liver diseases,21 including CHC,38 chronic hep-
atitis B (CHB),28 alcoholic liver disease29 and also
NAFLD.30 It was expected that FibroTest had a higher
performance for discriminating F3 vs. F4 than between
the other adjacent pairwise comparisons. This was true
also for liver biopsy,31, 39 even that 25 mm in length, due
to the greater differences in the area of ﬁbrosis between F3
vs. F4 than between the other adjacent stages, as demon-
strated when large surgical biopsies were used as a true
‘gold standard’.31 Relative to FibroTest, biopsy was
affected even more in the discrimination between F1 vs.
F2, as the inter- and intra-observer variability was greater
than for other adjacent stage comparisons, such as F3 vs.
F4.31, 40 Despite the signiﬁcant NonBinAUROC of
FibroTest and similar estimates for cirrhosis (5.7% vs.
5.5%), we observed that the prevalence of presumed F2
(6.5%) and F3 (10.7%) ﬁbrosis stages was lower than that
observed using biopsy (23.3% and 20.2%), respectively. It
is not necessarily correct to conclude that FibroTest
underestimated these two stages. It could also be related to
a lower quantity of ﬁbrosis in perisinusoidal ﬁbrosis than
in periportal ﬁbrosis. The F2 METAVIR is based on ‘few
septa’ and F3 on ‘many septa’ vs. ‘bridging’ for the SAF
ﬁbrosis score F3. A standardisation, such as the area of
collagen,41 on large biopsies could be useful in determin-
ing whether FibroTest underestimated or the SAF score
overestimated the ‘severity’ of ﬁbrosis in NAFLD before
proposing new cutoffs.
ActiTest could have limitations for NAFLD, as it was
originally designed for grading the necrotico-inﬂamma-
tory histological activity (four grades only) in patients
with CHC or CHB. These patients presented more hepa-
tocyte necrosis than NAFLD, with higher levels of ActiT-
est mostly related to higher ALT values and lower apoA1
values.42 However, we conﬁrmed here that ActiTest Non-
BinAUROC in NAFLD also increased very signiﬁcantly
with ballooning and intralobular inﬁltrates grades7, 10 but
Table 2 | Performance (non binary AUROC) of FibroTest, ActiTest and SteatoTest for the prediction of histological
SAF scores of ﬁbrosis, necro-inﬂammatory activity and steatosis
n = 600 Primary endpoint
Non binary AUROC
Signiﬁcance vs. 0.500
Blood test SAF score Mean 95% CI P-value
FibroTest Fibrosis F0–F4 0.878 0.864–0.892 <0.0001
ActiTest Activity A0–A4 0.846 0.830–0.862 <0.0001
SteatoTest SteatoTest S0–S3 0.822 0.804–0.840 <0.0001
Table 3 | Comparison between FibroTest-ActiTest and BARD, FIB4 and NAFLD score for the diagnostic of histological
ﬁbrosis and activity estimated by SAF scoring system
n = 574 Primary endpoint
Non binary AUROC
Signiﬁcance
Blood test SAF score Mean 95% CI P-value vs. FibroTest
FibroTest Fibrosis F0–F4 0.877 0.862–0.892 1
BARD Fibrosis F0–F4 0.836 0.820–0.852 0.0001
FIB4 Fibrosis F0–F4 0.845 0.829–0.861 0.007
NAFLD score Fibrosis F0–F4 0.866 0.850–0.882 0.26
Blood test SAF score Mean 95% CI P-value vs. ActiTest
ActiTest Activity A0–A4 0.846 0.830–0.862 1
BARD Activity A0–A4 0.810 0.792–0.828 0.0003
FIB4 Activity A0–A4 0.798 0.780–0.816 <0.0001
NAFLD score Activity A0–A4 0.815 0.805–0.825 0.005
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Figure 2 | Box plots of FibroTest (a), ActiTest (b) and SteatoTest (c) according to the respective SAF scoring systems.
600 cases were included. Signiﬁcance between stages/grades were estimated using NonBinROC measures and
detailed in Table 2. The median FibroTest values increased steadily (NonBinROC P < 0.001) with ﬁbrosis stages after
F1, ranging from 0.18 in F0 (n = 122), 0.21 in F1 (n = 184), 0.28 in F2 (n = 140), 0.41 in F3 (n = 121) and 0.71 in
cirrhosis (n = 33), all differences between adjacent stages were signiﬁcant (Bonferroni test P < 0.05). The median
value of ActiTest increased steadily (NonBinROC P < 0.001) from 0.21 for A0 (n = 64), 0.28 for A1 (n = 86), 0.35 for
A2 (n = 191) and 0.38 for A3 (n = 156) and 0.46 for A4 (n = 103). Only the differences between 2 grades were
signiﬁcant (Bonferroni test P < 0.05). The median value of SteatoTest increased (NonBinROC P = 0.002) from 0.52
for S0 (n = 20), 0.62 for S1 (n = 188), 0.66 for S2 (n = 228), to 0.71 for S3 (n = 163). The only signiﬁcant difference
was observed between grades was between S3 and S1 (Bonferroni test P < 0.05).
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in lower ranges than in viral hepatitis.42 The lower preva-
lence of presumed A2 (10.3%), A3 (5.5%) and A4 (9.1%)
grades vs. those observed using biopsy (31.8%, 26.0% and
17.2%, respectively) suggested, therefore, that cutoffs
could be modiﬁed. In these tertiary NAFLD populations
with a low prevalence of A0 and A1, a simpler classiﬁca-
tion focusing on the most severe NASH features, as sug-
gested by the FLIP algorithm, would be more
appropriate.4 However, in a primary general population,
the sensitivity of ActiTest is an advantage for detecting
early grades of ballooning or intralobular inﬂammation.
SteatoTest had similar limitations. It was originally
designed to quantify steatosis using four grades, up to
66% hepatocytes, and with a high sensitivity, as validated
with an S1 category deﬁned as fewer than 5% hepato-
cytes with steatosis. SteatoTest was not designed to dis-
criminate between severe steatosis (greater than 66%) vs.
marked steatosis (between 33% and 66%). Therefore, due
to the spectrum effect, it was expected that the NonBi-
nAUROC would be low in a tertiary centre population
of NAFLD, as steatosis was suspected in almost all
patients. Indeed, more than 5% steatosis was observed at
biopsy in 94% of patients, with only 20 patients classiﬁed
as S0. The potential advantages of SteatoTest are its abil-
ity to identify subjects with steatosis from those without
steatosis in the general population27 or in patients with
chronic viral hepatitis C,20 and its prognostic value in
patients with metabolic disorders.30
This study focused on three tests developed by several
co-authors of the article, who have an obvious conﬂict of
interest as inventor or employee of the company market-
ing these tests. However, the other co-authors were
totally independent, and they recruited the patients and
performed the assay independent of the company and
had full access to all data and analyses.
We compared directly FibroTest and ActiTest to pop-
ular nonpatented NITs, BARD, FIB4 and NAFLD score,
but not several others, such as APRI, fatty liver index,
ELF, Fibrospect, Fibrometer and transient elastography
(TE) for ﬁbrosis, cytokeratin 18, ultrasonography, mag-
netic resonance imaging and spectroscopy for steatosis.1
Other components with different rational such as adipo-
nectin, a hepatoprotective adipocytokine with insulin
sensitising properties could also be interesting for the
diagnosis of NAFLD features.41 A recent retrospective
comparison of nine NITs in 452 cases with presumed
NAFLD, used the biopsy NASH-CRN scoring system as
reference.11 Similar NonBinAUROC were observed,
0.698, 0.722, 0.730, 0.748, 0.763, for BARD, FibroTest,
NAFLD score, FIB4 and FibroMeterNAFLD, respectively.
Only the Fibrometer designed for viral hepatitis had a
small increase in NonBinAUROC vs. the 8 other NITs
(P = 0.04). TE had 14% of failure and the NonBinROC
was not assessed in intention to diagnose.
Here, FibroTest had signiﬁcantly higher NonBi-
nAUROC than BARD and FIB4 scores for ﬁbrosis pre-
diction. Furthermore, FibroTest had signiﬁcantly higher
median values between adjacent stage F2 and stage F1,
contrarily to BARD, FIB4 and NAFLD score (Bonferroni
test P < 0.05).
We acknowledge that NAFLD score, a noncommercial
inexpensive test, despite lower performance for discrimi-
nating stage-F2 vs. F1, was not inferior to FibroTest for
the main endpoint (NonBinAUROC).
These differences with other direct comparisons11
could be due to variability in the histological endpoint,
SAF being more reproducible than CREN scoring system,
but also to differences in ﬁbrosis spectrum between stud-
ies. The obvious advantages of nonpatented NITs were
their lower price than patented NITs, but their applicabil-
ity as well as their risk of false positives and false negatives
have been less investigated than for FibroTest.1
One advantage of FibroTest over the other NITs,
including TE,43 is its assessment together with ActiTest a
validated marker of necro-inﬂammatory histological
activity.44 Therefore, in patients with presumed NAFLD
and contrarily to any other NITs, it is possible to assess
the severity of these two independent features, deﬁning
the overall severity of NAFLD.4 The results of the pre-
sent study showed a higher prediction for activity (bal-
looning and lobular inﬂammatory) vs. the BARD, FIB4
and NAFLD scores. An advantage of FibroTest is the
absence of ALT and AST as components of a ﬁbrosis
panel. ALT elevations decrease with age and cirrhosis
and therefore should not be used as a component of
ﬁbrosis panels.1, 23, 44, 45
Methodology
We used a methodology in accordance with the speciﬁc
guidelines for testing non-invasive biomarkers in chronic
liver diseases.19 When performances of tests were not
compared directly in the same patients, the spectrum
effect must be taken into account.2, 17, 18 The perfor-
mances of tests expressed by standard binary AUROCs
or predictive values with standard cutoffs are dependent
upon the prevalence of each stage/grade. The indirect
comparisons of non-invasive test performances in
NAFLD patients vs. CHC patients are therefore
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potentially misleading, and so may not be fairly dis-
cussed in guidelines and reviews.1
A superﬁcial binary analysis of the present results (File
S3) for the prediction of cirrhosis (F4) could have con-
cluded that the performance of FibroTest observed in
NAFLD was ‘excellent’, with the standard (binary)
AUROC for the prediction of F4 vs. F0 = 0.903 (95% CI,
0.831–0.975), even better to CHC in which a median of
0.860 (range 0.710–0.920) was observed in 11 studies.46
For the prediction of ﬁbrosis (F1 vs. F2), the performance
of FibroTest in NAFLD could be classiﬁed as ‘poor’, with
the standard AUROC = 0.592 (95% CI, 0.530–0.654)
lower than a ‘fair’ classiﬁcation in CHC with a median of
0.790 (range 0.700–0.890) as observed in 25 studies.46
If the spectrum effect is not taken into account, the
diagnostic performance of FibroTest in NAFLD could be
overestimated due a much higher prevalence of F0 (24%)
compared with CHC, in which the prevalence of F0 was
2.4% in the larger database of CHC with biopsy published
[supplement S1 in Ref. 23]. Comparisons between the
present results in NAFLD vs. a large population of CHC
(n = 1289)47 found that the AUROCs between adjacent
stages were lower only for F1 vs. F2 and for F2 vs. F3.
Advantages of the SAF scoring system as a reference
The validation of the SAF scoring system 3,4 has been a
major breakthrough for NAFLD research, just as the
METAVIR scoring system for patients with chronic viral
hepatitis was 20 years ago.5 By the late 1990s, the ‘old
and confusing’ deﬁnitions of active or inactive hepatitis
had become obsolete. It was necessary to analyse the sever-
ity of ﬁbrosis and the severity necro-inﬂammatory activity
separately. This enabled identiﬁcation of the prognostic
value of ﬁbrosis progression to cirrhosis, the development
of non-invasive biomarkers (which are now recommended
at baseline in CHC and CHB), acceleration of the inclusion
of expensive direct acting antivirals (DAA) in phase-3 trials
in CHC, and most recently, prioritisation of the reimburse-
ment of these DAA according to ﬁbrosis severity.
In comparison with CHC, the deﬁnitions of NAFL vs.
NASH in NAFLD are potentially confusing as they com-
bine SAF. While a single lesion might be highly repro-
ducible, lower reproducibility is expected in a composite
diagnosis based on a combination of features such as
NASH. The SAF scoring system now facilitates the separa-
tion of these three elementary features and so should
accelerate the validation of non-invasive biomarkers.
Using the SAF scoring system and expressed by Non-
BinROC, these tests had similar performances as when
using the previous references, including the consensual
METAVIR scoring system for ﬁbrosis and activity in
CHC and CHB2 or the less consensual adapted META-
VIR scores in patients with NAFLD for ﬁbrosis, and
activity.10 This new validation, employing the SAF scor-
ing system speciﬁcally designed for NAFLD, clariﬁes the
utility of these blood tests as non-invasive alternatives to
biopsy.
Advantages of FLIP and FibroFrance-NAFLD cohorts
The overall population was very homogenous and was
clearly distinct from the population of alcohol drinkers,
as two-thirds of patients never drank other than very
occasionally. The FLIP project allowed us to validate the
diagnostic value of the non-invasive biomarkers (FibroT-
est, SteatoTest and ActiTest) in a large, nationally diverse
cohort independent from the inventor of the tests. Fibro-
France also had the advantage of prospectively following
all types of chronic liver diseases since 1996, with routine
non-invasive biomarkers introduced in 2002.
The aim of the present study was not to claim for a
near perfect panel of NITs, but to conﬁrm the signiﬁcant
performances of these tests in non-NAFLD patient. Our
aim was in line with the recommendations of scientiﬁc
societies such as EASL. In patients with presumed
NAFLD, we improve the validation of NITs already rec-
ommended for viral hepatitis.
In conclusion, this study conﬁrmed that FibroTest,
ActiTest and SteatoTest are non-invasive tests that may
offer an alternative to biopsy and correlate with grade
and stage of the three elementary features of NAFLD:
ﬁbrosis, inﬂammatory activity and steatosis.
SUPPORTING INFORMATION
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